Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus - Pfizer

Drug Profile

Sirolimus - Pfizer

Alternative Names: AY 22989; CYPHER; CYPHER SELECT PLus; NEVO; NPC-12; NPC-12G; NPC-12T; NSC 226080; NSC 606698; Rapalimus; Rapamune; Rapamycin

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Boston Childrens Hospital; Cordis Corporation; Food and Drug Administration; Gifu Pharmaceutical University; Keio University; Kyoto University; Le Bonheur Children's Hospital; National Center for Advancing Translational Sciences; Nobelpharma; Osaka University; Pfizer; Showa University; Wyeth
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action B cell inhibitors; Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis; Lymphangioleiomyomatosis; Renal transplant rejection
  • Registered Fibroma
  • Phase III Haematological disorders
  • Phase II/III Fibrodysplasia ossificans progressiva; Neurofibromatoses
  • Phase II Epilepsy; Kasabach-Merritt syndrome; Systemic lupus erythematosus
  • Phase I/II Sensorineural hearing loss
  • Discontinued Autosomal dominant polycystic kidney disease; Mycoses

Most Recent Events

  • 30 Sep 2019 Nobelpharma plans a clinical trial in Angiofibroma (Nobelpharma pipeline, July 2019)
  • 30 Jul 2019 Phase-I/II clinical trials in Sensorineural hearing loss (Pendred syndrome) in Japan (unspecified route) (Nobelpharma pipeline, July 2019)
  • 30 Jul 2019 Phase-II clinical trials in Epilepsy (epilepsy with focal cortical dysplasia type II) in Japan (unspecified route) (Nobelpharma pipeline, July 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top